Prestige Biopharma believes in the potential of biosimilars and the contribution they make towards establishing a sustainable future for biologic medicines. Our goal is to enhance patient treatment accessibility by offering biological medicines that are affordable, safe, and of high quality. Our portfolio consists of 12 biosimilars, including, HD201 (trastuzumab biosimilar) currently under regulatory review, HD204 (bevacizumab biosimilar) in Phase 3 clinical study and PBP1502 (adalimumab biosimilar) in Phase 1 clinical study.

Development Stage